Recently, OpenAI and Anthropic have introduced new healthcare-focused AI products, signaling a shift in how artificial intelligence is integrated into medical services. While doctors acknowledge the value of AI in healthcare, there's skepticism about the effectiveness of chatbot interfaces specifically for this industry.
Converge Bio, a startup specializing in AI-driven drug discovery, has successfully raised $25 million in a Series A funding round. The round was led by Bessemer Venture Partners and included investment from notable executives at Meta, OpenAI, and Wiz, highlighting strong confidence from leading technology innovators.
OpenAI announced its acquisition of health-tech company Torch for $100 million. The company plans to integrate Torch's capabilities with its recently introduced healthcare tool, ChatGPT Health, to enhance medical technology solutions.
McKinsey shares insights on how to successfully implement or refine health and wellbeing programs that positively impact both employees and organizational performance.
In November, Fast Company collaborated with Johns Hopkins to host the inaugural World Changing Ideas Summit in Washington, DC, bringing together leaders from business and academia to discuss innovations defining our future. Leaders in space exploration, healthcare, and artificial intelligence shared their insights on what key challenges and breakthroughs to expect in 2026.
Akhila Kosaraju, CEO of Pharebio, highlights a pressing race against antibiotic resistance. Using cutting-edge AI, her company aims to develop 15 novel antibiotics by 2030 to outmaneuver bacteria that rapidly develop resistance. Kosaraju stresses the urgency of accelerating drug development timelines to deliver effective treatments sooner.
Saleem Miyan, CEO of Max Space, emphasizes the critical need for continued American presence in space following the planned 2030 retirement of the International Space Station. His firm is working to innovate and maintain U.S. leadership through new space stations, ensuring strength in exploration and security.
Molly Mulligan, COO of SpaceMD, shares the exciting potential to advance drug development by leveraging microgravity to grow antibody crystals. Inspired by previous successes on the International Space Station, the company aims to bring new medicines from space research to market.
Ben Wolf, Chief Medical Officer at Isomorphic Labs (a Google DeepMind spinout), focuses on harnessing AI to tackle complex diseases such as cancer through precision medicine—customizing treatments for individual patients. With promising AI technology like AlphaFold, human trials are approaching.
Together, these leaders highlight 2026 as a year of urgent innovation and collaboration across sectors to address global health, space exploration, and AI-driven medical breakthroughs.
Anthropic has introduced its new healthcare-focused AI, Claude for Healthcare, just a week following OpenAI's launch of their ChatGPT Health product.
Nvidia and Eli Lilly have formed a multiyear collaboration to establish an AI-driven drug discovery lab. This partnership connects Eli Lilly's drug development pipeline with Nvidia's upcoming hardware advancements, aiming to accelerate medical breakthroughs through more efficient and integrated research cycles.
Haemonetics Corporation has acquired the Galway-based medtech company Vivasure Medical for €185 million. This acquisition is aimed at accelerating the development and market reach of Vivasure's PerQseal technology, enhancing its capabilities and commercial footprint.
AI chatbot developers are increasingly offering health advice directly to consumers. This shift raises important questions about the accuracy and safety of AI-generated medical guidance.
Anthropic is aggressively advancing in the AI healthcare sector, pushing boundaries while Google encounters challenges with AI-generated medical information.
